Market News

Ocugen’s Partner Bharat Biotech Reveals Positive Covaxin Trial Data in Children

Biopharmaceutical company Ocugen’s (OCGN) partner Bharat Biotech has announced positive results from a Phase 2/3 trial of Covaxin, conducted in India, in children aged 2-18 years.

The candidates were administered two doses after a gap of 28 days and showed antibody response similar to adults. About 93% reduction in severe disease was witnessed. Also, none of the participants experienced any severe adverse events during the trial.

The Chairman of the Board, CEO and Co-Founder of Ocugen, Shankar Musunuri, PhD, MBA, said, “These data represent the first positive vaccine data in children as young as two years of age and come at an important time as COVID-19 infections are seeing a spike across the globe.”

Wall Street’s Take

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Ocugen with a price target of $10 (107% upside potential).

The rest of the Street is cautiously optimistic about the stock and has a Moderate Buy consensus rating based on 2 Buys and 1 Hold. The average Ocugen price target of $10.33 implies 113.9% upside potential.

Smart Score

According to TipRanks’ Smart Score system, OCGN gets a 6 out of 10, which indicates that Ocugen is likely to perform in line with market averages. Download the mobile app now, available on iOS and Android.

Related News:
Roku Expands Its TV Ready Certification Program
Velocity Financial Acquires Majority Stake in Century Health
Sutro and Tasly Enter Agreement to Develop STRO-002 in Greater China

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More